Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
B7-H3 is a common oncogene found in various cancer types. However, the molecular mechanisms underlying abnormal B7-H3 expression and colorectal cancer (CRC) progression need to be extensively explored. B7-H3 was upregulated in human CRC tissues and its abnormal expression was correlated with a poor prognosis in CRC patients. Notably, gain- and loss-of-function experiments revealed that B7-H3 knockdown substantially inhibited cell proliferation, migration, and invasion , whereas exogenous B7-H3 expression yielded contrasting results. In addition, silencing of B7-H3 inhibited tumor growth in a xenograft mouse model. Mechanistically, our study demonstrated that the N6-methyladenosine (m6A) binding protein YTHDF1 augmented B7-H3 expression in an m6A-dependent manner. Furthermore, rescue experiments demonstrated that reintroduction of B7-H3 considerably abolished the inhibitory effects on cell proliferation and invasion induced by silencing YTHDF1. Our results suggest that the YTHDF1-m6A-B7-H3 axis is crucial for CRC development and progression and may represent a potential therapeutic target for CRC treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10839442 | PMC |
| http://dx.doi.org/10.1016/j.isci.2024.108956 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NUTM2A-AS1 as a potential key regulator in cancer: unraveling its ceRNA networks and impact on tumor biology.
Eur J Med Res
September 2025
Dentistry School, Shiraz University of Medical Sciences, Shiraz, Iran.
NUTM2A-AS1 is an emerging long noncoding RNA (lncRNA) that has garnered significant attention due to its multifaceted roles in cancer biology. As a member of the ceRNA network, NUTM2A-AS1 modulates gene expression by sequestering microRNAs, thereby influencing key oncogenic pathways. This review aims to provide a comprehensive overview of the current understanding of NUTM2A-AS1 in the development, progression, and metastasis of various cancers, including gastric cancer, hepatocellular carcinoma, neuroblastoma, colorectal cancer, glioma, lung adenocarcinoma, prostate cancer, and renal cell carcinoma.
View Article and Find Full Text PDFPreclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer.
J Immunother Cancer
September 2025
The Comprehensive Breast Care Center, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, Shaanxi, China
Background: Triple-negative breast cancer (TNBC) represents a subtype of breast cancer with poorest prognosis due to limited effective targeted therapies. Chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable efficacy in treating hematological cancers, but its application in TNBC requires further development. One major obstacle is the lack of suitable tumor-specific target in TNBC.
View Article and Find Full Text PDFTargeting B7-H3 in Cancer-Associated Fibroblasts Using Nanosystems Suppresses Anaplastic Thyroid Carcinoma Progression.
Thyroid
September 2025
Department of Ultrasound, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Anaplastic thyroid carcinoma (ATC) represents a rare yet highly malignant histotype of thyroid cancer. Cancer-associated fibroblasts (CAFs) play a pivotal role in tumor cell invasion, migration, and angiogenesis and present a potential target for cancer treatment. We aimed to investigate the effects of modulating specific subsets of CAFs on the proliferation, invasion, and migration of ATC.
View Article and Find Full Text PDFSmall cell lung cancer (SCLC): At the door of targeted therapies.
Biomol Biomed
August 2025
College of Medicine, QU Health, Qatar University, Doha, Qatar.
Small-cell lung cancer (SCLC) is a tobacco-associated neuroendocrine tumor comprising ~15% of lung cancers (~150,000 cases/year). For decades, outcomes stagnated: most patients present with extensive-stage disease, screening rarely detects early tumors, surgery is seldom feasible, and platinum-etoposide remained the first-line standard with median overall survival (OS) <12 months. Radiotherapy (including consolidative thoracic RT) and prophylactic cranial irradiation or MRI surveillance offered incremental gains.
View Article and Find Full Text PDFB7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment.
Pathol Oncol Res
August 2025
Clinical Collaboration Unit Translational Immunology, Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany.
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide. Despite advances in various treatment approaches, outcomes for patients with metastatic CRC (mCRC) remain poor, and treatment-associated side effects significantly impact quality of life. While immunotherapy has shown promise in certain malignancies, its efficacy in CRC is limited to a minority of patients, highlighting the urgent need for novel therapeutic targets to improve treatment efficacy while minimizing off-target effects.
View Article and Find Full Text PDF